Yellow Fever Vaccine. V. Antibody Response in Monkeys Inoculated with Graded Doses of the 17D Vaccine
AUTOR(ES)
Mason, Richard A.
RESUMO
A dosage equal to or greater than approximately 3.4 Dex (decimal exponent, log10) weanling mouse intracerebral 50% lethal dose (LD50) was sufficient to elicit a yellow fever antibody response, as determined by the plaque neutralization (PN) test, in better than 90% of vaccinated rhesus monkeys. Lower dosages were progressively less effective in terms of PN titers and the PN and hemagglutination-inhibition serological conversion rates observed. A dose of between 3.4 and 4.2 Dex weanling mouse intracerebral LD50, or one-tenth to one times the dosage recommended for man, provided an optimal antibody response in monkeys. In rhesus monkeys, in contrast to the findings for man, pre-existing yellow fever antibody did not interfere with the antibody response to yellow fever vaccine. The PN test was felt to be a more sensitive and specific indicator of yellow fever antibody in rhesus monkeys after vaccination than the hemagglutination inhibition or complement fixation tests.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=380469Documentos Relacionados
- Yellow Fever Vaccine: Direct Challenge of Monkeys Given Graded Doses of 17D Vaccine
- Is a dose of 17D vaccine in the current context of Yellow Fever enough?
- Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it.
- Single shot of 17D vaccine may not confer life-long protection against yellow fever
- Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization
